A Reappraisal of Thymosin Alpha1 in Cancer Therapy

Frontiers in Oncology

Volumn 9, Issue , 2019, Pages

  Costantini, Claudio ^a   Bellet, Marina M ^a   Pariano, Marilena ^a   Renga, Giorgia ^a   Stincardini, Claudia ^a   Goldstein, Allan L ^b   Garaci, Enrico ^c   Romani, Luigina ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c Faculty of Architecture and Industrial Design   (Italy)

Author keywords

checkpoint inhibitors; colitis; dendritic cells; immunotherapy; thymosin alpha1

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CHECKPOINT KINASE INHIBITOR; ENTECAVIR; ETOPOSIDE; FAMCICLOVIR; GEMCITABINE; IFOSFAMIDE; INTERLEUKIN 2; LAMIVUDINE; SORAFENIB; THYMOSIN ALPHA1; VINORELBINE TARTRATE;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SCREENING; CANCER THERAPY; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSPLANTATION; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LONG TERM SURVIVAL; LUNG CANCER; MELANOMA; NONHUMAN; PROTEIN EXPRESSION; REVIEW; TUMOR MICROENVIRONMENT; TUMOR VOLUME; UPREGULATION; XENOGRAFT;

EID: 85072845795     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2019.00873     Document Type: Review

References (109)

1. Goldstein AL, Asanuma Y, White A. The thymus as an endocrine gland: properties of thymosin, a new thymus hormone. Recent Prog Horm Res. (1970) 26:505–38. 10.1016/B978-0-12-571126-5.50016-94394273
2. Goldstein AL. The Gordon Wilson lecture. The history of the development of thymosin: chemistry, biology and clinical applications. Trans Am Clin Climatol Assoc. (1977) 88:79–94. 331647
3. Goldstein AL. History of the discovery of the thymosins. Ann N Y Acad Sci. (2007) 1112:1–13. 10.1196/annals.1415.04517600284
4. Goldstein AL, Slater FD, White A. Preparation, assay, and partial purification of a thymic lymphocytopoietic factor (thymosin). Proc Natl Acad Sci USA. (1966) 56:1010–7. 10.1073/pnas.56.3.10105230175
5. Asanuma Y, Goldstein AL, White A. Reduction in the incidence of wasting disease in neonatally thymectomized CBA-W mice by the injection of thymosin. Endocrinology. (1970) 86:600–10. 10.1210/endo-86-3-6004391388
6. Law LW, Goldstein AL, White A. Influence of thymosin on immunological competence of lymphoid cells from thymectomized mice. Nature. (1968) 219:1391–2. 10.1038/2191391a05678029
7. Goldstein AL, Asanuma Y, Battisto JR, Hardy MA, Quint J, White A. Influence of thymosin on cell-mediated and humoral immune responses in normal and in immunologically deficient mice. J Immunol. (1970) 104:359–66. 4904881
8. Hooper JA, McDaniel MC, Thurman GB, Cohen GH, Schulof RS, Goldstein AL. Purification and properties of bovine thymosin. Ann N Y Acad Sci. (1975) 249:125–44. 10.1111/j.1749-6632.1975.tb29063.x236717
9. Goldstein AL, Low TL, McAdoo M, McClure J, Thurman GB, Rossio J. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci USA. (1977) 74:725–9. 10.1073/pnas.74.2.725265536
10. Schulof RS. Thymic peptide hormones: basic properties and clinical applications in cancer. Crit Rev Oncol Hematol. (1985) 3:309–76. 10.1016/S1040-8428(85)80035-43902261
11. Baskies AM, Ommaya AK, Chretien PB. Thymosin alpha1: First clinical trial and comparison with thymosin fraction 5. In: Serrou B, Rosenfeld C, Daniels JC, Saunders JP, editors. Current Concepts in Human Immunology and Cancer Immunomodulation. Amsterdam: Elsevier Biomedical Press (1982). p. 567–74.
12. Smalley RV, Talmadge J, Oldham RK, Thurman GB. The thymosins–preclinical and clinical studies with fraction V and alpha-I. Cancer Treat Rev. (1984) 11:69–84. 10.1016/0305-7372(84)90017-36234058
13. Ishitsuka H, Umeda Y, Nakamura J, Yagi Y. Protective activity of thymosin against opportunistic infections in animal models. Cancer Immunol Immunother. (1983) 14:145–50. 10.1007/BF002053526404549
14. Umeda Y, Sakamoto A, Nakamura J, Ishitsuka H, Yagi Y. Thymosin alpha 1 restores NK-cell activity and prevents tumor progression in mice immunosuppressed by cytostatics or X-rays. Cancer Immunol Immunother. (1983) 15:78–83. 10.1007/BF00199694
15. Ishitsuka H, Umeda Y, Sakamoto A, Yagi Y. Protective activity of thymosin alpha 1 against tumor progression in immunosuppressed mice. Adv Exp Med Biol. (1983) 166:89–100. 10.1007/978-1-4757-1410-4_96650286
16. Favalli C, Jezzi T, Mastino A, Rinaldi-Garaci C, Riccardi C, Garaci E. Modulation of natural killer activity by thymosin alpha 1 and interferon. Cancer Immunol Immunother. (1985) 20:189–92. 10.1007/BF002055743851698
17. Pica F, Mastino A, Grelli S, Jezzi T, Favalli C. Combined treatment with thymosin alpha 1 and interferon enhances NK activity in immunosuppressed tumor bearing mice. J Chemother. (1989) 1(4 Suppl.):1167–9. 16312818
18. Favalli C, Mastino A, Jezzi T, Grelli S, Goldstein AL, Garaci E. Synergistic effect of thymosin alpha 1 and alpha beta-interferon on NK activity in tumor-bearing mice. Int J Immunopharmacol. (1989) 11:443–50. 10.1016/0192-0561(89)90172-02807622
19. Garaci E, Mastino A, Favalli C. Enhanced immune response and antitumor immunity with combinations of biological response modifiers. Bull N Y Acad Med. (1989) 65:111–9. 2481523
20. Pica F, Fraschetti M, Matteucci C, Tuthill C, Rasi G. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma. Anticancer Res. (1998) 18:3571–8. 9858941
21. Mastino A, Favalli C, Grelli S, Innocenti F, Garaci E. Thymosin alpha 1 potentiates interleukin 2-induced cytotoxic activity in mice. Cell Immunol. (1991) 133:196–205. 10.1016/0008-8749(91)90191-D1991327
22. Sztein MB, Serrate SA. Characterization of the immunoregulatory properties of thymosin alpha 1 on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes. Int J Immunopharmacol. (1989) 11:789–800. 10.1016/0192-0561(89)90133-12599716
23. Leichtling KD, Serrate SA, Sztein MB. Thymosin alpha 1 modulates the expression of high affinity interleukin-2 receptors on normal human lymphocytes. Int J Immunopharmacol. (1990) 12:19–29. 10.1016/0192-0561(90)90064-T2303316
24. Mastino A, Favalli C, Grelli S, Rasi G, Pica F, Goldstein AL. Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice. Int J Cancer. (1992) 50:493–9. 10.1002/ijc.29105003271735618
25. Lopez M, Carpano S, Cavaliere R, Di Lauro L, Ameglio F, Vitelli G. Biochemotherapy with thymosin alpha 1, interleukin-2 and dacarbazine in patients with metastatic melanoma: clinical and immunological effects. Ann Oncol. (1994) 5:741–6. 10.1093/oxfordjournals.annonc.a0589797826907
26. Rasi G, Terzoli E, Izzo F, Pierimarchi P, Ranuzzi M, Sinibaldi-Vallebona P. Combined treatment with thymosin-alpha1 and low dose interferon-alpha after dacarbazine in advanced melanoma. Melanoma Res. (2000) 10:189–92. 10.1097/00008390-200010020-0001210803720
27. Maio M, Mackiewicz A, Testori A, Trefzer U, Ferraresi V, Jassem J. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. J Clin Oncol. (2010) 28:1780–7. 10.1200/JCO.2009.25.5208
28. Danielli R, Fonsatti E, Calabro L, Di Giacomo AM, Maio M. Thymosin alpha1 in melanoma: from the clinical trial setting to the daily practice and beyond. Ann N Y Acad Sci. (2012) 1270:8–12. 10.1111/j.1749-6632.2012.06757.x23050811
29. Danielli R, Cisternino F, Giannarelli D, Calabro L, Camerini R, Savelli V. Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy. Expert Opin Biol Ther. (2018) 18(Suppl. 1):77–83. 10.1080/14712598.2018.149471730063847
30. King RS, Tuthill C. Evaluation of thymosin alpha 1 in nonclinical models of the immune-suppressing indications melanoma and sepsis. Expert Opin Biol Ther. (2015) 15(Suppl. 1):S41–9. 10.1517/14712598.2015.100844625643200
31. Li W, Song L, Wu S, Xue X, Zhang L, He L. Expression, purification and characterization of a novel soluble human thymosin alpha1 concatemer exhibited a stronger stimulation on mice lymphocytes proliferation and higher anti-tumor activity. Int J Biol Sci. (2011) 7:618–28. 10.7150/ijbs.7.61821647330
32. Li J, Cheng Y, Zhang X, Zheng L, Han Z, Li P. The in vivo immunomodulatory and synergistic anti-tumor activity of thymosin alpha1-thymopentin fusion peptide and its binding to TLR2. Cancer Lett. (2013) 337:237–47. 10.1016/j.canlet.2013.05.00623684552
33. Wang F, Xu C, Peng R, Li B, Shen X, Zheng H. Effect of a C-end rule modification on antitumor activity of thymosin alpha1. Biochimie. (2018) 154:99–106. 10.1016/j.biochi.2018.08.00130096371
34. Wang F, Li B, Fu P, Li Q, Zheng H, Lao X. Immunomodulatory and enhanced antitumor activity of a modified thymosin alpha1 in melanoma and lung cancer. Int J Pharm. (2018) 547:611–20. 10.1016/j.ijpharm.2018.06.04129933059
35. Wang F, Yu T, Zheng H, Lao X. Thymosin alpha1-Fc modulates the immune system and down-regulates the progression of melanoma and breast cancer with a prolonged half-life. Sci Rep. (2018) 8:12351. 10.1038/s41598-018-30956-y30120362
36. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. (2010) 7:448–58. 10.1038/nrgastro.2010.10020628345
37. Mutchnick MG, Goldstein AL. In vitro thymosin effect on T lymphocytes in alcoholic liver disease. Clin Immunol Immunopathol. (1979) 12:271–80. 10.1016/0090-1229(79)90030-8313287
38. Mutchnick MG, Missirian A, Johnson AG. Lymphocyte cytotoxicity in human liver disease using rat hepatocyte monolayer cultures. Clin Immunol Immunopathol. (1980) 16:423–37. 10.1016/0090-1229(80)90184-17408232
39. Mutchnick MG, Schaffner JA, Prieto JA, Weller FE, Goldstein AL. Increased thymic hormone responsive suppressor T lymphocyte function in chronic active hepatitis. Dig Dis Sci. (1983) 28:328–34. 10.1007/BF013249496219866
40. Mutchnick MG, Appelman HD, Chung HT, Aragona E, Gupta TP, Cummings GD. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology. (1991) 14:409–15. 10.1002/hep.18401403021874487
41. Davis GL. Treatment of chronic hepatitis B. Hepatology. (1991) 14:567–9. 10.1016/0270-9139(91)90199-6
42. Rezakovic I, Mondazzi L, Asti L, Ideo G. Thymosin a1 versus a2 interferon treatment of HBsAg, HBeAb, HBV-DNA positive chronic active hepatitis. Hepatology. (1992) 16:67A.
43. Andreone P, Cursaro C, Gramenzi A, Zavagliz C, Rezakovic I, Altomare E. A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody–and hepatitis B virus DNA–positive chronic hepatitis B. Hepatology. (1996) 24:774–7. 10.1053/jhep.1996.v24.pm00088551758855175
44. Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology. (1998) 27:1383–7. 10.1002/hep.5102705279581695
45. Mutchnick MG, Ehrinpreis MN, Kinzie JL, Peleman RR. Prospectives on the treatment of chronic hepatitis B and chronic hepatitis C with thymic peptides and antiviral agents. Antiviral Res. (1994) 24:245–57. 10.1016/0166-3542(94)90071-X7526795
46. Mutchnick MG, Lindsay KL, Schiff ER, Cummings GD, Appelman HD, Peleman RR. Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. J Viral Hepat. (1999) 6:397–403. 10.1046/j.1365-2893.1999.00181.x10607256
47. Zavaglia C, Severini R, Tinelli C, Franzone JS, Airoldi A, Tempini S. A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B. Dig Dis Sci. (2000) 45:690–6. 10.1023/A:100543132394510759236
48. Rasi G, Mutchnick MG, Di Virgilio D, Sinibaldi-Vallebona P, Pierimarchi P, Colella F. Combination low-dose lymphoblastoid interferon and thymosin alpha 1 therapy in the treatment of chronic hepatitis B. J Viral Hepat. (1996) 3:191–6. 10.1111/j.1365-2893.1996.tb00094.x8871880
49. Saruc M, Yuceyar H, Kucukmetin N, Demir MA, Kandiloglu AR. Combination thymosin-alpha 1 and interferon-alpha 2b in the treatment of anti-HBe-positive chronic hepatitis B in Turkey. Hepatogastroenterology. (2002) 49:798–802. 10.1016/S0016-5085(08)81888-412063993
50. Lim SG, Wai CT, Lee YM, Dan YY, Sutedja DS, Wee A. A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B. Antivir Ther. (2006) 11:245–53. 16640105
51. Saruc M, Ozden N, Turkel N, Ayhan S, Hock LM, Tuzcuoglu I. Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B. J Pharm Sci. (2003) 92:1386–95. 10.1002/jps.1040112820143
52. Kim BH, Lee YJ, Kim W, Yoon JH, Jung EU, Park SJ. Efficacy of thymosin alpha-1 plus peginterferon alpha-2a combination therapy compared with peginterferon alpha-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study. Scand J Gastroenterol. (2012) 47:1048–55. 10.3109/00365521.2012.69490222726105
53. Rasi G, DiVirgilio D, Mutchnick MG, Colella F, Sinibaldi-Vallebona P, Pierimarchi P. Combination thymosin alpha 1 and lymphoblastoid interferon treatment in chronic hepatitis C. Gut. (1996) 39:679–83. 10.1136/gut.39.5.6799026482
54. Rezakovic I, Zavaglia C, Bottelli R, Ideo G. A pilot study of thymosin alpha 1 therapy in chronic active hepatitis C. Hepatology. (1993) 18:252A. 10.1016/0270-9139(93)92530-D
55. Andreone P, Cursaro C, Gramenzi A, Buzzi A, Covarelli MG, Di Giammarino L. A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C. Liver. (1996) 16:207–10. 10.1111/j.1600-0676.1996.tb00729.x8873009
56. Sherman KE, Sjogren M, Creager RL, Damiano MA, Freeman S, Lewey S. Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. Hepatology. (1998) 27:1128–35. 10.1002/hep.5102704309537454
57. Moscarella S, Buzzelli G, Romanelli RG, Monti M, Giannini C, Careccia G. Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: preliminary results. Liver. (1998) 18:366–9. 10.1111/j.1600-0676.1998.tb00819.x9831367
58. Andreone P, Gramenzi A, Cursaro C, Felline F, Loggi E, D'Errico A. Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial. J Viral Hepat. (2004) 11:69–73. 10.1046/j.1365-2893.2003.00470.x14738560
59. Moshier JA, Mutchnick MG, Dosescu J, Holtz TK, Akkary S, Mahakala K. Thymosin-alpha 1, but not interferon-alpha, specifically inhibits anchorage-independent growth of hepatitis B viral transfected HepG2 cells. J Hepatol. (1996) 25:814–20. 10.1016/S0168-8278(96)80283-2
60. Yared G, Hussain KB, Nathani MG, Moshier JA, Dosescu J, Mutchnick MG. Cytokine-mediated apoptosis and inhibition of virus production and anchorage independent growth of viral transfected hepatoblastoma cells. Cytokine. (1998) 10:586–95. 10.1006/cyto.1998.03409722931
61. Andreone P, Cursaro C, Gramenzi A, Margotti M, Ferri E, Talarico S. In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C. J Viral Hepat. (2001) 8:194–201. 10.1046/j.1365-2893.2001.00285.x11380797
62. Lau GK, Nanji A, Hou J, Fong DY, Au WS, Yuen ST. Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase. J Viral Hepat. (2002) 9:280–7. 10.1046/j.1365-2893.2002.00361.x12081605
63. Zhang YY, Chen EQ, Yang J, Duan YR, Tang H. Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis. Virol J. (2009) 6:63. 10.1186/1743-422X-6-6319467157
64. Qu L, Tian Z, Bao X, Lyu Y, Lyu J. Entecavir versus entecavir-thymosin alpha-1 combination therapy for chronic hepatitis B: a meta-analysis. Mod J Integr Tradit Chin West Med. (2015) 9.
65. Wu X, Shi Y, Zhou J, Sun Y, Piao H, Jiang W. Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study. Expert Opin Biol Ther. (2018) 18(Suppl. 1):61–9. 10.1080/14712598.2018.145151130063860
66. Poo JL, Sanchez-Avila F, Kershenobich D, Garcia-Samper X, Gongora J, Uribe M. Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study. J Gastroenterol Hepatol. (2004) 19(Suppl. 6):S79–81. 10.1111/j.1440-1746.2004.03634.x
67. Baek YH, Lee SW, Yoo HS, Yoon HA, Kim JW, Kim YH. Thymosin alpha-1 in combination with pegylated interferon and ribavirin in chronic hepatitis c patients who have failed to prior pegylated interferon and ribavirin treatment. Gut Liver. (2007) 1:87–9. 10.5009/gnl.2007.1.1.8720485665
68. Abbas Z, Hamid SS, Tabassum S, Jafri W. Thymosin alpha 1 in combination with interferon alpha and ribavirin in chronic hepatitis C patients who are non-responders or relapsers to interferon alpha plus ribavirin. J Pak Med Assoc. (2004) 54:571–4.
69. Poo JL, Sanchez Avila F, Kershenobich D, Garcia Samper X, Torress-Ibarra R, Gongora J. Efficacy of triple therapy with thymalfasin, peginterferon alpha-2a, and ribavirin for the treatment of hispanic chronic HCV nonresponders. Ann Hepatol. (2008) 7:369–75. 10.1016/S1665-2681(19)31839-319034238
70. Ciancio A, Andreone P, Kaiser S, Mangia A, Milella M, Sola R. Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role? J Viral Hepatol. (2012) 19(Suppl. 1):52–9. 10.1111/j.1365-2893.2011.01524.x
71. He C, Peng W, Li C, Wen TF. Thymalfasin, a promising adjuvant therapy in small hepatocellular carcinoma after liver resection. Medicine. (2017) 96:e6606. 10.1097/MD.000000000000660628422855
72. Liang YR, Guo Z, Jiang JH, Xiang BD, Li LQ. Thymosin alpha1 therapy subsequent to radical hepatectomy in patients with hepatitis B virus-associated hepatocellular carcinoma: a retrospective controlled study. Oncol Lett. (2016) 12:3513–8. 10.3892/ol.2016.512127900029
73. Stefanini GF, Foschi FG, Castelli E, Marsigli L, Biselli M, Mucci F. Alpha-1-thymosin and transcatheter arterial chemoembolization in hepatocellular carcinoma patients: a preliminary experience. Hepatogastroenterology. (1998) 45:209–15. 9496515
74. Gish RG, Gordon SC, Nelson D, Rustgi V, Rios I. A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. Hepatol Int. (2009) 3:480–9. 10.1007/s12072-009-9132-319669251
75. Shuqun C, Mengchao W, Han C, Feng S, Jiahe Y, Wenming C. Combination transcatheter hepatic arterial chemoembolization with thymosin alpha1 on recurrence prevention of hepatocellular carcinoma. Hepatogastroenterology. (2004) 51:1445–7. 15362772
76. Shuqun C, Mengchao W, Han C, Feng S, Jiahe Y, Wenming C. Antiviral therapy using lamivudine and thymosin alpha1 for hepatocellular carcinoma coexisting with chronic hepatitis B infection. Hepatogastroenterology. (2006) 53:249–52. 16608033
77. Gu X, Jiang Z, Yang M. Efficacy of sorafenib with thymosin a1 for patients with advanced hepatocellular carcinoma. Jiangsu Med J. (2010) 10.
78. Schulof RS, Chorba TL, Cleary PA, Palaszynski SR, Alabaster O, Goldstein AL. T-cell abnormalities after mediastinal irradiation for lung cancer. The in vitro influence of synthetic thymosin alpha-1. Cancer. (1985) 55:974–83. 10.1002/1097-0142(19850301)55:5<974::AID-CNCR2820550510>3.0.CO;2-I3155644
79. Schulof RS, Lloyd MJ, Cleary PA, Palaszynski SR, Mai DA, Cox JW, Jr. A randomized trial to evaluate the immunorestorative properties of synthetic thymosin-alpha 1 in patients with lung cancer. J Biol Response Mod. (1985) 4:147–58. 3998766
80. Garaci E, Mastino A, Pica F, Favalli C. Combination treatment using thymosin alpha 1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice. Cancer Immunol Immunother. (1990) 32:154–60. 10.1007/BF017714502126987
81. Garaci E, Lopez M, Bonsignore G, Della Giulia M, D'Aprile M, Favalli C. Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a. Eur J Cancer. (1995) 31A:2403–5. 10.1016/0959-8049(95)00477-78652276
82. Salvati F, Rasi G, Portalone L, Antilli A, Garaci E. Combined treatment with thymosin-alpha1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: a phase-II controlled trial. Anticancer Res. (1996) 16:1001–4. 8687090
83. Jiang J, Wang X, Tian J, Li L, Lin Q. Thymosin plus cisplatin with vinorelbine or gemcitabine for non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials. Thorac Cancer. (2011) 2:213–20. 10.1111/j.1759-7714.2011.00057.x27755854
84. Yuan C, Zheng Y, Zhang B, Shao L, Liu Y, Tian T. Thymosin alpha1 promotes the activation of myeloid-derived suppressor cells in a Lewis lung cancer model by upregulating Arginase 1. Biochem Biophys Res Commun. (2015) 464:249–55. 10.1016/j.bbrc.2015.06.13226111447
85. Moody TW, Fagarasan M, Zia F, Cesnjaj M, Goldstein AL. Thymosin alpha 1 down-regulates the growth of human non-small cell lung cancer cells in vitro and in vivo. Cancer Res. (1993) 53:5214–8. 8221658
86. Moody TW, Leyton J, Zia F, Tuthill C, Badamchian M, Goldstein AL. Thymosinalpha1 is chemopreventive for lung adenoma formation in A/J mice. Cancer Lett. (2000) 155:121–7. 10.1016/S0304-3835(00)00405-510822126
87. Moody TW. Thymosin alpha1 as a chemopreventive agent in lung and breast cancer. Ann N Y Acad Sci. (2007) 1112:297–304. 10.1196/annals.1415.04017567944
88. Kharazmi-Khorassani J, Asoodeh A. Thymosin alpha-1; a natural peptide inhibits cellular proliferation, cell migration, the level of reactive oxygen species and promotes the activity of antioxidant enzymes in human lung epithelial adenocarcinoma cell line (A549). Environ Toxicol. (2019) 34:941–9. 10.1002/tox.2276531067016
89. Bo C, Wu Q, Zhao H, Li X, Zhou Q. Thymosin alpha1 suppresses migration and invasion of PD-L1 high-expressing non-small-cell lung cancer cells via inhibition of STAT3-MMP2 signaling. Onco Targets Ther. (2018) 11:7255–70. 10.2147/OTT.S17794330425517
90. Lao X, Liu M, Chen J, Zheng H. A tumor-penetrating peptide modification enhances the antitumor activity of thymosin alpha 1. PLoS ONE. (2013) 8:e72242. 10.1371/journal.pone.007224223977262
91. Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J Clin. (2012) 62:309–35. 10.3322/caac.2013222576456
92. Kelly PN. The cancer immunotherapy revolution. Science. (2018) 359:1344–5. 10.1126/science.359.6382.134429567702
93. Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buque A, Senovilla L, Baracco EE. Classification of current anticancer immunotherapies. Oncotarget. (2014) 5:12472–508. 10.18632/oncotarget.299825537519
94. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. (2018) 359:1350–5. 10.1126/science.aar406029567705
95. Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. (2019) 18:197–218. 10.1038/s41573-018-0007-y30610226
96. Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. (2019) 16:563–80. 10.1038/s41571-019-0218-031092901
97. Giuliani C, Napolitano G, Mastino A, Di Vincenzo S, D'Agostini C, Grelli S. Thymosin-alpha1 regulates MHC class I expression in FRTL-5 cells at transcriptional level. Eur J Immunol. (2000) 30:778–86.3.3. 10.1002/1521-4141(200003)30:3<778::AID-IMMU778>3.3.CO;2-910741392
98. Ritter B, Greten FR. Modulating inflammation for cancer therapy. J Exp Med. (2019) 216:1234–43. 10.1084/jem.2018173931023715
99. Samaan MA, Pavlidis P, Papa S, Powell N, Irving PM. Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. Nat Rev Gastroenterol Hepatol. (2018) 15:222–34. 10.1038/nrgastro.2018.1429512649
100. Romani L, Bistoni F, Perruccio K, Montagnoli C, Gaziano R, Bozza S. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood. (2006) 108:2265–74. 10.1182/blood-2006-02-00476216741252
101. Romani L, Oikonomou V, Moretti S, Iannitti RG, D'Adamo MC, Villella VR. Thymosin alpha1 represents a potential potent single-molecule-based therapy for cystic fibrosis. Nat Med. (2017) 23:590–600. 10.1038/nm.430528394330
102. Wang F, Yin Q, Chen L, Davis MM. Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade. Proc Natl Acad Sci USA. (2018) 115:157–61. 10.1073/pnas.171290111529255057
103. Perez-Ruiz E, Minute L, Otano I, Alvarez M, Ochoa MC, Belsue V. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature. (2019) 569:428–32. 10.1038/s41586-019-1162-y31043740
104. Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF. The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies. Science. (2018) 359:1366–70. 10.1126/science.aar691829567708
105. Del Prete A, Scutera S, Sozzani S, Musso T. Role of osteopontin in dendritic cell shaping of immune responses. Cytokine Growth Factor Rev. (2019). 10.1016/j.cytogfr.2019.05.004 [Epub ahead of print]. 31126876
106. Inoue M, Shinohara ML. Intracellular osteopontin (iOPN) and immunity. Immunol Res. (2011) 49:160–72. 10.1007/s12026-010-8179-521136203
107. Fan X, He C, Jing W, Zhou X, Chen R, Cao L. Intracellular Osteopontin inhibits toll-like receptor signaling and impedes liver carcinogenesis. Cancer Res. (2015) 75:86–97. 10.1158/0008-5472.CAN-14-061525398438
108. Kanayama M, Xu S, Danzaki K, Gibson JR, Inoue M, Gregory SG. Skewing of the population balance of lymphoid and myeloid cells by secreted and intracellular osteopontin. Nat Immunol. (2017) 18:973–84. 10.1038/ni.379128671690
109. Messmer MN, Netherby CS, Banik D, Abrams SI. Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy. Cancer Immunol Immunother. (2015) 64:1–13. 10.1007/s00262-014-1639-325432147